Chinese traditional healthcare products are attracting more attention from the world, but they need international clinical evaluation before they can find a ready international market, said Dr. Harry Genant, Chairman of Osteoporosis Task Force of World Health Organization (WHO) here on Sunday.
At China Forum on Healthcare products, Genant said the U.S. Synarc Company, the world largest imaging research institute, has found in a multi-center clinical trial that some Chinese healthcare products were effective in increasing bone-density of osteoporosis patients.
The Chairman said those products lacking clinical evaluation can not prove themselves scientifically. This has become the main obstacle for them to enter the world market.
Ma Jianwen, Chairman of Osteoporosis Fund of China Development Foundation for Science and Technology, said there are various kinds of bone-healthcare products in China of different qualities, and most of them have not passed clinical trials. Some products of poor quality have severely lowered the trust of the people to healthcare products as a whole.
Dr.Zhang Yaoshen, a senior consultant of Healthcare Product Evaluation Committee of China State Food & Drug Administration Bureau, said the government pays much attention to the safety of healthcare products, takes measures to ensure the healthy development of this market and pave the way for Chinese traditional healthcare products to the world market.
He stressed that it is of great importance to conduct re-evaluation of China's healthcare products.